Key Takeaways
- ITeos Therapeutics is ceasing operations and intends to return a significant portion of its cash reserves to investors.
- The decision follows disappointing clinical trial results for its anti-TIGIT antibody, belrestotug, in partnership with GSK.
- iTeos plans to sell its oncology programs but anticipates significant costs associated with employee terminations and winding down operations.
ITeos Therapeutics Concludes Operations
ITeos Therapeutics, based in Belgium, has announced it will wind down its operations following disappointing clinical trial results for its anti-TIGIT antibody, belrestotug. The company, which previously collaborated with GlaxoSmithKline (GSK), aimed to deliver promising study outcomes but encountered lower-than-expected progression-free survival data mid-May. Furthermore, results from another Phase 2 trial solidified their decision to terminate efforts related to belrestotug.
In light of these developments, ITeos plans to move quickly to ensure investor value, reflecting a $600 million-plus cash stockpile. The company, which reported $624.3 million in cash at the end of March, intends to generate additional funds by selling two Phase 1 oncology programs: the ENT1 inhibitor EOS-984 and the anti-TREM2 antibody EOS-215. Additionally, ITeos is exploring the sale of a preclinical obesity program targeting ENT1.
The closure of ITeos’ operations will incur several costs, estimated between $21.8 million and $24.7 million related to employee termination expenses. The firm employed 173 individuals as of last year, and operational shut down in Belgium will follow a consultation process. Moreover, costs related to contract and lease terminations are anticipated, though exact figures remain unavailable. Approximately $11.1 million is projected for the winding down of other clinical development activities.
Despite the challenges, ITeos aims to complete the winding down process by the third quarter of this year, although the conclusion of its clinical development activities will take longer. This swift closure contrasts with the typical drawn-out processes seen in the biotech industry, which often includes lengthy searches for strategic alternatives and slow pivots to other projects.
The announcement of the wind-down led to a notable investor response, with company shares rising by 28% to nearly $11 in premarket trading, reflecting some confidence in management’s plan to recover value for shareholders during this transition. As the market observes ITeos’ next movements, focus will likely remain on how effectively the company can liquidate its remaining assets and manage its substantial cash resource amid the industry’s challenges.
The content above is a summary. For more details, see the source article.